Inactivation of the most important tumour suppressor gene TP53 occurs in most, if not all,
human cancers. Loss of functional wild-type p53 is achieved via two main mechanisms …

Mutations in the p53 gene compromise its role as guardian of genomic integrity, yielding
predominantly missense p53 mutant proteins. The gain-of-function hypothesis has long …

The TP53 tumor suppressor gene is mutated early in most of the patients with triple-negative
breast cancer (TNBC). The most frequent TP53 alterations are missense mutations that …

Simple Summary Cancer cells often become resistant to treatment, making it harder to fight
the disease effectively. This resistance can happen due to genetic changes, proteins that …

Triple‐negative breast cancer (TNBC) is the most malignant subtype of breast cancer. TP53,
which has a mutation rate of≈ 70%–80% in TNBC patients, plays oncogenic roles when …

Simple Summary Patient-specific factors must be thoroughly analyzed to minimize the side
effects of applied treatments. This study examined the radiobiological response of …

Patients with triple-negative breast cancer (TNBC) have a poor prognosis due to the lack of
effective molecular targets for therapeutic intervention. Here we found that the long …

New treatments are urgently required for triple-negative breast cancer (TNBC). As TP53 is
mutated in approximately 80% of TNBC, it is theoretically an attractive target for new drugs …

Purpose The incidence of triple-negative breast cancer (TNBC) in India is higher compared
to Western populations. The objective of this study is to identify novel and less reported …

Simple Summary An inhibitor of BUB1 increases the cytotoxic ability of different classes of
chemotherapy, targeted agents, and radiotherapy in triple-negative breast cancer, which is …